Pulsenmore signs first U.S. home ultrasound deal
Pulsenmore Ltd. reported its first commercial engagement with a medical center in the United States for its home pregnancy ultrasound service.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Pulsenmore Ltd. reported its first commercial engagement with a medical center in the United States for its home pregnancy ultrasound service. This follows recent FDA clearance for the company’s home-use pregnancy ultrasound product.
On January 29, 2026, Pulsenmore, through a subsidiary, signed a services agreement with the Center for Fetal Medicine & Women’s Ultrasound, a fetal medicine and women’s ultrasound center operating from two locations in the Los Angeles area. Under this agreement, the center will purchase Pulsenmore ES home ultrasound services so pregnant patients can be remotely monitored and reduce unnecessary in-clinic diagnostic visits, with a particular focus on high-risk pregnancies.
Insights
Pulsenmore signs its first U.S. commercial deal after FDA clearance, beginning paid deployment of its home pregnancy ultrasound service.
The company has moved from regulatory clearance to its first commercial engagement in the U.S., via a services agreement with the Center for Fetal Medicine & Women’s Ultrasound in Los Angeles. The medical center will purchase Pulsenmore ES home ultrasound services for remote pregnancy monitoring, especially for high-risk obstetric care.
This agreement validates that at least one specialized U.S. provider is willing to pay for Pulsenmore’s technology, linking earlier FDA clearance to real-world clinical use. The initial deployment is described as gradual and responsible, indicating an incremental roll-out rather than large-scale adoption from day one.
Management frames the deal as an important milestone in its U.S. strategic plan and highlights substantial clinical and business potential in that market. Actual financial impact will depend on usage levels and any future agreements with additional centers, which would be discussed in subsequent company disclosures.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Pulsenmore (PLSM) announce in its latest 6-K filing?
Which U.S. medical center is working with Pulsenmore (PLSM) on home ultrasound services?
How will the Pulsenmore ES service be used under the new U.S. agreement?
How does FDA clearance relate to Pulsenmore’s new U.S. commercial deal?
What market opportunity does Pulsenmore (PLSM) see in the United States?
What is Pulsenmore’s core technology focus according to the filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of February 2026
001-43033
(Commission File Number)
PULSENMORE LTD.
(Exact name of Registrant as specified in its charter)
8 Omarim St.
Omer 8496500, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
On February 2, 2026, Pulsenmore Ltd. issued a press release entitled “Pulsenmore Announces First Commercial Engagement with a Leading U.S.-Based Medical Center”. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
EXHIBIT INDEX
Exhibit No. |
Description | |
| 99.1 | Press Release, dated February 2, 2026. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Pulsenmore Ltd. | ||
| Date: February 2, 2026 | By: | /s/ Eran Hirsh |
| Eran Hirsh | ||
| Chief Financial Officer | ||
Exhibit 99.1
Pulsenmore Announces First Commercial Engagement with a Leading U.S.-Based Medical Center
OMER, Israel, Feb 2, 2026 /PRNewswire/ — Pulsenmore Ltd. (NASDAQ, TASE: PLSM), a pioneer in home ultrasound technology, today announced a first commercial engagement with a medical center in the United States, following receipt of FDA approval for its home pregnancy ultrasound product.
On January 29, 2026, the Company (through its subsidiary) entered into a services agreement with the Center for Fetal Medicine & Women’s Ultrasound, a fetal medicine and women’s ultrasound center located in LA California (the “CFFM”).
Under the agreement, CFFM will purchase Pulsenmore ES home ultrasound services, enabling patients to benefit from remote monitoring while reducing unnecessary visits to the diagnostic center.
Pulsenmore redefines prenatal care through clinically validated home ultrasound and telehealth technology, addressing one of the fastest-growing needs in global healthcare: high-quality care delivered beyond the clinic. Positioned at the intersection of digital health, telemedicine, and femtech, Pulsenmore enables remote prenatal monitoring that improves access and continuity of care and enhances patient experience.
CFFM is a prenatal diagnostic center in California that provides a wide range of specialized services and includes multidisciplinary experts in maternal-fetal medicine. The center manages approximately 1,500 pregnancies per year, operates from two locations in the Los Angeles area and specializes in obstetric care for high-risk pregnancies
“Pulsenmore’s ultrasound system marks a new era in maternal-fetal care, empowering expectant mothers with safe, guided access to ultrasound imaging from home or work, while keeping clinicians closely connected throughout the entire process.” said Dr. Lawrence Platt, head of CFFM.
Dr. Elazar Sonnenschein, CEO of Pulsenmore, commented: “We are pleased to announce today Pulsenmore’s first commercial agreement in the United States, marking another significant step forward following our recent FDA clearance. The agreement with CFFM, a highly professional and leading medical center specializing in the management of high-risk pregnancies, represents an important milestone in the implementation of our strategic plan in the U.S. market, where we see substantial clinical and business potential.
This agreement will enable the deployment of a remote pregnancy monitoring model that places the patient and her needs at the center of care. This collaboration allows us to begin operating in a gradual and responsible manner in a market where many women face limited access to obstetric healthcare services, and to demonstrate how home-based ultrasound can become an integral part of routine medical care.”
About Pulsenmore
Pulsenmore Ltd. is dedicated to revolutionizing maternal health through the development of home-use ultrasound technology that connect mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine, Pulsenmore makes prenatal care patient-centric, expanding access and improving continuity of care. For more information, visit www.pulsenmore.com
This press release contains forward-looking statements. In particular, statements using words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “contemplate,” “do not believe,” “aim,” “goal,” “due,” “predict,” “plan,” “project,” “continue,” “potential,” “positioned,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. Such forward-looking statements include, but are not limited to, statements relating to the expected outcome of Pulsenmore’s engagement with CFFM. Forward-looking statements reflect Pulsenmore’s current views, plans, or expectations with respect to future events or financial performance. They are inherently subject to significant business, economic, competitive, and other risks, uncertainties, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, but not limited to, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales, marketing and distribution channels; security, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the SEC, including, but not limited to, the risks, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033), filed with the SEC on December 29, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as otherwise required by law.
Investor Contact:
Miri Segal-Scharia
MS-IR LLC
msegal@ms-ir.com